Presentation TCT 2023 PROs are a Powerful Endpoint in TR Interventional Trials Presenter: Suzanne V. Arnold October 25, 2023 REGISTER for free or LOG IN to view this content Structural Heart TCT 2023 Tricuspid Valve Up Next Presentation TCT 2023 PROs Alone in Non-Blinded Studies Shouldn’t Drive Device Approval Presenter: Nir Uriel October 25, 2023 More slides + Presentation TCT 2023 Intentional Coronary Revascularization Versus Conservative Therapy in Patients, who Underwent Successful Peripheral Artery Revascularization due to Critical Limb Ischemia - the INCORPORATE Randomized Clinical Trial Presenter: Gabor G. Toth October 25, 2023 Presentation TCT 2023 Angiographic and Clinical Outcomes of the Thin-Strut MAGNITUDE Bioresorbable Scaffold in Patients with Below-the-Knee Arterial Disease: Early Results from the RESOLV I Trial Presenter: Eric A. Secemsky October 25, 2023 We Recommend Disclosures Nothing to disclose
Presentation TCT 2023 PROs Alone in Non-Blinded Studies Shouldn’t Drive Device Approval Presenter: Nir Uriel October 25, 2023
Presentation TCT 2023 Intentional Coronary Revascularization Versus Conservative Therapy in Patients, who Underwent Successful Peripheral Artery Revascularization due to Critical Limb Ischemia - the INCORPORATE Randomized Clinical Trial Presenter: Gabor G. Toth October 25, 2023
Presentation TCT 2023 Angiographic and Clinical Outcomes of the Thin-Strut MAGNITUDE Bioresorbable Scaffold in Patients with Below-the-Knee Arterial Disease: Early Results from the RESOLV I Trial Presenter: Eric A. Secemsky October 25, 2023